Join MySLAS Social

Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cells Lines

 

Read this Article

Paul A. Johnston, Ph.D.
Associate Professor
Department of Pharmaceutical Sciences
School of Pharmacy
University of Pittsburgh
Pittsburgh, PA, USA
 
Paul A. Johnston, Ph.D., has 30 years of drug discovery experience in the pharmaceutical, biotechnology and academic sectors. An innovator of cell-based lead generation, he pioneered the implementation of high-content imaging technology for drug discovery. In 2005, he helped create the University of Pittsburgh Molecular Library Screening Center, where he led 21 HTS campaigns and reconfigured the NCI 60 panel for cancer drug combination screening. In 2011, Johnston established his own chemical biology laboratories at the University of Pittsburgh in the Department of Pharmaceutical Sciences, School of Pharmacy, to conduct research on the application of novel drug discovery strategies to find new and effective drugs or drug combinations for prostate cancer, melanoma, head and neck cancer and hepatocellular carcinoma. He provides expertise in HTS/HCS assay development and implementation for drug discovery collaborations in other therapeutic areas.

A founding member of the Society for Biomolecular Imaging and Informatics, Johnston has been a member of SBS/now SLAS since 1998, and he chairs the HCS/HCA data and informatics special interest group.

Websites

University of Pittsburgh
LinkedIn
U.S. National Library of Medicine

Other SLAS Publications

Dudgeon D, Shinde, SN, Hua, Y, Shun, TY, Lazo, JS, Strock, CJ, Giuliano, KA, Taylor, DL, Johnston, PA, and Johnston, PA. Implementation of a 220,000 Compound HCS Campaign to Identify Disruptors of the Interaction between p53 and hDM2, and Characterization of the Confirmed Hits. J Biomol Screen. 2010. 15: 766-782.

Close DA, Wang AX, Kochanek SJ, Shun T, Eiseman JL, Johnston PA. Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) Database. SLAS Discov. 2019 Mar;24(3):242-263.

Kochanek SJ, Close DA, Wang AX, Shun T, Empey PE, Eiseman JL, Johnston PA. Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy. SLAS Discov. 2019 Apr 30:653-668.

Kochanek SJ, Close DA, Camarco DP, Johnston PA. Maximizing the Value of Cancer Drug Screening in Multicellular Tumor Spheroid Cultures: A Case Study in Five Head and Neck Squamous Cell Carcinoma Cell Lines. SLAS Discov. 2020 Jan 25:1-21.


SLAS publishes two PubMed:MEDLINE-indexed journals and accepts manuscripts on an ongoing basis from members and non-members.  > READ MORE

March 20, 2020